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MUNICIPALITIES OF HIGHER VULNERABILITY TO SYLVATIC YELLOW FEVER OCCURRENCE IN THE 
SÃO PAULO STATE, BRAZIL
Eduardo Stramandinoli MORENO & Rita de Cássia Barradas BARATA
SUMMARY
Until 1999 the endemic cases of Sylvatic Yellow Fever were located in the states of northern, midwestern and pre-Amazon regions. 
Since then, the disease progressively expanded its territory of occurrence, cases being registered beyond the traditional boundaries 
of endemism. The São Paulo State is considered to be part of this context, since after decades without registration of autochthonous 
cases of the disease, it reported, in 2000 and 2008-2009, epizootic occurrence in non-human primates and 30 cases in humans. Facts 
like these, added to the increase in incidences of serious adverse effects resulting from the Yellow Fever vaccination, have highlighted 
the importance of defining priority municipalities for vaccination against the disease in the state. Two groups of municipalities, some 
affected and some non-affected by YF, were compared for environmental variables related to the eco-epidemiology of the disease 
according to literature. The Multiple Correspondence Analysis (MCA) was used to pinpoint the factor able to differentiate the two 
groups of municipalities and define the levels of risk. The southeast region of the São Paulo State was considered to be the area with a 
higher number of municipalities classified as high risk and should be considered a priority for the application of prevention measures 
against Yellow Fever.
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INTRODUCTION
Yellow Fever (YF) shows two distinct epidemiological cycles, 
Sylvatic and Urban, which are distinguished fundamentally by the vector 
involved with the transmission and by the sources of infection8,11. The 
Sylvatic Yellow Fever (SYF) is endemic in tropical regions of Africa 
and the Americas. Cases of the disease have been reported between the 
parallels 12ºN and 12ºS25. In Brazil, the major period of occurrence of 
the disease is during the months from January to April, when increases 
are observed in both the rainfall patterns and the density of the vectors of 
the disease, coinciding with the period of major activity for agriculture 
and animal husbandry19,20,23.
Until 1999 the endemic cases were located in the states of northern, 
midwestern and pre-Amazon regions, as well as some sporadic cases in 
the western part of the Minas Gerais State2. Since then, Sylvatic Yellow 
Fever progressively expanded its territory of occurrence, a gradual 
increase in cases of the disease being observed near to the traditional 
boundaries of the endemic zone.
In the outbreaks that occurred in the period of 2000/2003, it 
was possible to observe an expansion of the viral circulation in the 
southeastern part of the country, its presence being detected in silent 
areas for decades, which imposed a need for a redefinition of risk areas3.
In 2000, two autochthonous human cases of Sylvatic Yellow Fever 
were reported in the northwestern region of the São Paulo State22. In 2008, 
more cases were reported in the same region, namely two autochthonous 
human cases confirmed in the region of Ribeirao Preto and epizootic 
occurrences in non-human primates confirmed in the region of São Jose 
do Rio Preto21. In 2009 cases emerged in the mid-southern region of the 
state, 30 human cases and epizootic occurrences in non-human primates 
being confirmed as YF2,10. The outbreaks occurred in five different 
municipalities, and led the Public Health authorities of the state to expand 
the area to be indicated for vaccination against Yellow Fever4,10.
In Brazil, up to 2008, four epidemiologically distinct zones were 
defined for Sylvatic Yellow Fever: the endemic zone (indicated for 
vaccination against YF), the transition zone (also known as the epizootic 
or emergency area), the potential risk zone (not indicated for vaccination 
against YF) and the indene zone (not indicated for vaccination against 
YF)3,5,12. The “transition” and “potential risk” zones did not have 
any registered human cases and so did not require any indication for 
vaccination against the disease. However, the fact that these areas share 
some boundaries with areas confirmed for circulation of Yellow Fever 
Virus (YFV) and present some favorable environmental conditions for 
the establishment and maintenance of YF generated the need for special 
attention, and resulted in them being monitored more closely. However, 
the criteria for the delimitation of these areas were largely subjective, and 
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the lack of vaccinations for populations considered to be at risk created 
some ethical problems for the public-health authorities of Brazil, who 
decided, from 2008, to eliminate the zones of “transition” and “potential 
risk”. So, the areas currently recognized are only the endemic (indicated 
for vaccination against YF) and indene (not indicated for vaccination 
against YF) areas.
The municipalities indicated for vaccination against YF, in 
emergency situations, like in an outbreak period, are considered to be 
“affected” or “vaccination-expanded” areas. Thus, municipalities which 
showed evidence of viral circulation, such as: epizootic occurrence in 
non-human primates confirmed for YF, as well as confirmed human 
cases or isolation of the virus in mosquito vectors, are considered to 
be “affected”8. Municipalities which are located up to 30 km from an 
affected municipality are considered to be “vaccination-expanded” areas.
The Yellow Fever vaccine used in Brazil is produced by the Oswaldo 
Cruz Foundation/Biomanguinhos, by the replication of the YFV strain 
17D (sub-strain 17DD) in Specific-Pathogen-Free chicken embryos. 
The vaccine was considered to be totally safe until 2001, up to which 
point there had been no reports of serious adverse effects related to its 
administration.
In 2001, however, 12 cases were described6,9,24, and an additional 39 
cases were reported worldwide up to 20091, totaling more than 50 cases 
until this moment1,15,16. Two types of serious adverse effects are commonly 
reported: neurotropic disease caused by the invasion of the vaccine strain 
into the central nervous system; and viscerotropic disease, a pansystemic 
infection that is frequently accompanied by hepatic failure, a condition 
closely related to the infection by the wild virus1,18.
The risk factors for the development of these two post-vaccination 
syndromes have not yet been adequately described. Some descriptive 
studies defined three main potential risk factors: 60 years of age or 
more7,17, male gender and a history of immunosuppression14. 
These facts have generated a dilemma for the public-health 
authorities: what proportion of the at-risk population should be vaccinated 
to minimize the total number of cases due to both the natural infection 
by YFV as well as the 17DD vaccine strain?
The public-health authorities of the São Paulo State are currently 
under pressure to define vaccination strategies for the containment of the 
geographic expansion of the disease. So, this study has as goals identifying 
risk areas for SYF in municipalities currently located outside of the area 
indicated for vaccination against YF in the São Paulo State, in order to 
identify those with higher vulnerability to the disease’s occurrence.
METHODS
Study Area: The São Paulo State is composed of 645 municipalities, 
of which 216 are currently located outside of the area indicated for 
vaccination against YF. The state operates a surveillance system divided 
into 33 Regional Groups (RG), in such a way that 13 of these are located 
in areas not indicated for vaccination against YF.
These municipalities represent the area with the highest population 
density in the state and one of the highest in the country.
Figure 1 shows the expansion over time of the areas indicated for 
vaccination against YF in the São Paulo State between 2000 and 2009, 
in accordance with the criteria of the Brazilian Ministry of Health.
Methodology for risk assessment: For the selection of variables 
related to exposition, vulnerability and resilience to Yellow Fever a case-
control design with an ecological approach was developed13,14.
To this end, cases were considered in municipalities with confirmed 
viral circulation (either epizootic occurrence in non-human primates or 
human cases confirmed by epidemiological or laboratorial criteria, or 
isolation of YFV in mosquito vectors); or municipalities with adjacent 
boundaries up to 30 km from an affected municipality.
The other municipalities of the state were considered as controls, 
since they were located at least 100 km from any affected municipality. 
For each group (both affected and non-affected), 30 municipalities 
were randomly selected and compared using the Qui-square test (5% 
significance) for variables potentially related to the eco-epidemiology 
of Yellow Fever. The variables shown to be associated with the 
viral circulation (p value < 0.05) were selected for the Multiple 
Correspondences Analysis (MCA).
Table 1 shows this group of variables and its respective weights 
(indicated by the MCA) to explain the total variability between the two 
groups of municipalities studied.
The MCA generated a factor, designated “F-factor”, which represents 
the level of vulnerability of each municipality to the occurrence of 
Yellow Fever in its territory, and is calculated by the sum of the weights 
attributed to each variable. 
The factor has an amplitude which varies from -5.5 to 5.5, such 
that values below 0 represent low risk, values from 0 to 2.0 represent 
medium risk and values above 2.0 represent high risk of the disease’s 
occurrence. Thus, the F-factor was calculated for the 216 municipalities 
in the area currently not indicated for vaccination against YF in the State 
of São Paulo.
Fig. 1 - Expansion over time of areas indicated for vaccination against Yellow Fever, São 
Paulo State, Brazil. 2000-2009.




According to the model, among the 216 municipalities located in 
areas currently not indicated for vaccination against Yellow Fever, 137 
(63.5%) showed low risk, 53 (24.5%) showed risk and 25 (12%) showed 
high risk.
Figure 2 shows the distribution of the 216 municipalities located in 
areas not indicated for vaccination against Yellow Fever, according to 
the F-factor:
DISCUSSION
The YF surveillance system in Brazil functions based on confirmed 
cases, not including in its objectives prediction of the disease’s 
occurrence in places with potential risk. The main goals of this system 
are principally focused on fast detection of cases of the disease for the 
rapid implementation of emergency measures, in order to prevent an 
epidemic outbreak3. The old approach to risk classification of YF in 
Brazil, which used areas of “transition” and “potential risk” to guide 
the control measures, allowed for the intensification of surveillance in 
those areas with known environmental potential for the establishment 
of the disease5,12. This approach, however, was highly subjective, since 
the criteria for area designation were not described in a systematic way. 
This generated difficulties in the implementation of action measures, and 
so it was simplified to the current method.
However, it is of extreme importance that a surveillance system 
like that for Yellow Fever - a fatal disease with a big epidemic potential 
- works with predictive models, so as to coordinate action measures 
in outbreak situations, as well as, in the long term, aiming to break 
the disease’s expansion into big populated areas or known vulnerable 
populations.
The application of this standardized methodology to the municipalities 
not indicated for vaccination against YF pointed towards the south-east 
region of the São Paulo State as the most vulnerable to the disease’s 
occurrence. In this region there is located a large Biodiversity Conservation 
Unit: The State Touristic Park of “Alto do Ribeira” (PETAR), and thus 
several attributes considered for the F-factor calculation are concentrated 
there. The region has more than 120 thousand hectares, constituting an 
ecologic continuum connecting affected areas with the most populated 
region in the state.
Another group classified “at risk” for SYF occurrence is located in 
the metropolitan region of the city of São Paulo, which has more than 20 
million inhabitants. Despite its extensive urban development, this region 
has patches of natural forest and environments potentially able to maintain 
the YFV. So, these municipalities could function as ‘stepping stones’ for 
the expansion of the virus in the direction of the most populated region 
of Brazil, potentially increasing the urban risk of YFV.
In this sense, it is recommended that RGs that are subject to 
epidemiologic surveillance, which have municipalities classified as 
“at risk” in its coverage area, pass through an analysis of its structural 
capacity for the confrontation of a Yellow Fever outbreak. This analysis 
should consider the following: the number of technicians trained and 
sensitized for the detection of YF suspected cases, its treatment and 
laboratorial diagnosis resources; viability for the detection of epizootic 
occurrence in non-human primates; capacity for the conduction of 
entomological studies; and viability for the timely implementation of 
vaccination campaigns for target populations when required.
In the case of RGs that have municipalities classified as “high risk”, 
it is recommended that, in addition to the measures cited above, in the 
short term, the following be carried out: the organization of a surveillance 
system for Icterohemorrhagic Fever Syndrome (SIHFS), once this system 
increased the sensibility of the Yellow Fever Surveillance System, in 
other regions of the state affected by the disease.
Table 1 
Weights for each variable used for the calculation of the F-factor, obtained by 
the MCA
Variables Weight
Distance for YF vaccination indicated area - till 30 km 0.306264
Distance for YF vaccination indicated area - 31 to 100 km 0.244947
Distance for YF vaccination indicated area - higher than 100 km -0.78091
Distance for Biodiversity conservation unite - till 30 km 0.648733
Distance for Biodiversity conservation unite - 31 to 100 km 0.013377
Distance for Biodiversity conservation unite - higher than 100 km -1.06924
Riparian forest proportion - till 30% -0.71405
Riparian forest proportion - 31 to 60% -0.24182
Riparian forest proportion - 61 to 100% 0.932843
Number of main routes of illegal wildlife traffic - Low -0.85655
Number of main routes of illegal wildlife traffic - Medium -0.65112
Number of main routes of illegal wildlife traffic - High 1.087954
Dominant Wind Route direction influence - Low -0.63524
Dominant Wind Route direction influence - Medium 0.073681
Dominant Wind Route direction influence - High 1.123113
Humidity - (Pluviosity/RET) - less than 1,5 -0.93357
Humidity (Pluviosity/RET) - higher than 1,5 0.400103
Surveillance for SFHS - Yes -0.64806
Surveillance for SFHS - No 0.847463
Fig. 2 - Distribution of municipalities located in areas not indicated for vaccination against 
YF, in accordance with F-factor.
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In the case that some of the high-risk regions are highly populated, 
it is recommended that RGs with higher populations be given priority. 
Currently, the region which greatest concentration of high-risk 
municipalities is the RG coverage area “Registro”, located in Vale do 
Ribeira, in the southeastern region of the state.
CONCLUSIONS
The southeastern region of the State of São Paulo (RG Registro) is the 
region with the highest vulnerability to the occurrence of Sylvatic Yellow 
Fever in its territory. These municipalities have priority for vaccination 
against the disease in the state. The methodology used in this study had 
as its objective municipalities differentiated according to its vulnerability 
to YF occurrence, identified by a systematic design. The utilization of 
predictive methodologies can help the health professionals involved to 
make decisions during vaccination campaigns. Whether re-incorporated 
into the Yellow Fever Surveillance System as a complementary tool 
or not, predictive methodologies like this must be standardized and 
contextualized for each state or region, in order to avoid the subjectivity 
and difficulty of implementation of methods used in the past.
RESUMO
Municípios de alta vulnerabilidade à ocorrência da febre amarela 
silvestre no Estado de São Paulo, Brasil
Até o ano de 1999, no Brasil, casos endêmicos de Febre Amarela 
Silvestre estavam localizados nos estados das regiões Norte, Centro-
Oeste e pré-amazônica. Desde então, a doença vem progressivamente 
expandindo seu território de ocorrência, sendo registrados casos além das 
fronteiras tradicionais de endemismo. Neste contexto se insere o estado de 
São Paulo que, após décadas sem registro de casos autóctones da doença, 
reportou em 2000 e 2008-2009 epizootias em primatas não humanos e 
30 casos humanos. Fatos como este, somados a crescente incidência de 
eventos adversos graves relacionados à vacinação contra Febre Amarela, 
demonstram a importância de serem definidos municípios prioritários para 
a vacinação contra a doença no estado. Assim, dois grupos de municípios, 
afetados e não-afetados pela Febre Amarela, foram comparados para 
variáveis ambientais relacionadas com a eco-epidemiologia da doença 
segundo a literatura. A Análise por Correspondência Múltipla foi utilizada 
para gerar um fator capaz de diferenciar os dois grupos de municípios e 
definir os níveis de risco. Após aplicação da metodologia para os municípios 
atualmente localizados fora da área de recomendação de vacinação contra 
Febre Amarela, a região sudeste do estado foi considerada prioritária para 
aplicação de medidas preventivas contra a doença.
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